JPRN-jRCT2031220132招募中未知
Special drug-use survey of Tarlige (central neuropathic pain)
Matsuoka for Yomei0 个研究点目标入组 400 人开始时间: 2022年6月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients with central neuropathic pain not treated with Tarlige before
- •(2) Patients who started administration of Tarlige during the contract period (contract period based on the contract with each medical site)
- •(3) Patients who started administration of Tarlige during the registration period
- •(4) Patients from whom written informed consent was obtained
排除标准
- 未提供
研究者
相似试验
已完成
Unknown
Special drug-use survey of Tarlige (evaluation of the efficacy in patients with peripheral neuropathic pain)JPRN-jRCT1080224913DAIICHI SANKYO CO., LTD1,890
进行中（未招募）
不适用
Special drug-use survey of Tarlige tablet (evaluation of safety in long-term use)JPRN-jRCT2031200212Matsuoka Yomei900
已完成
不适用
Special Drug Use Results Survey of Targretin capsules 75-mg in patients with Cutaneous T-cell LymphomasCutaneous T-Cell LymphomasJPRN-UMIN000022568Minophagen Pharmaceutical Co., Ltd.200
招募中
不适用
Special Drug Use-results Survey of Targretin Capsules combined with photo(chemo)therapyCutaneous T-cell lymphomaJPRN-jRCT2031210625pharmacovigilance departmant70
招募中
不适用
Protocol Number; CINC280AJP01MET exon 14 skipping mutation-positive unresectable advanced/recurrent non-small cell lung cancerJPRN-jRCT2031200409Sugimoto Toshiya100